ReviewAmerican journal of clinical dermatology2024
Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance.
Review in American journal of clinical dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 30 citations in OpenAlex.
- Natural Product-Inspired Antifungal Drugs Introduced for Human Use from 1872 to August 2026.Antibiotics (Basel, Switzerland) · 2026Review
- Emerging Global Patterns of Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Trichophyton indotineae: Rise, Diagnosis, Treatment, and Future Directions.American journal of clinical dermatology · 2026Review
- Unraveling CARD9 Mutations in Deep Dermatophytosis: A Genetic Gateway to Fungal Invasion and Immune Dysfunction.Journal of fungi (Basel, Switzerland) · 2026Review
- Review
- Long-term spatio-temporal trends in burden of fungal skin diseases in middle-aged and elderly people from 1990 to 2021.PLoS neglected tropical diseases · 2026Article
- The Evolving Landscape of Dermatophytosis in the UAE: Trichophyton indotineae and Related Genotypes.Mycoses · 2026Article
- Combined itraconazole and terbinafine therapy for pediatric kerion: a report of two cases.Translational pediatrics · 2026Article
- Diagnostic challenges and the evolving landscape of tinea infections.AME case reports · 2026Article
- Sodium new houttuyfonate inhibits the growth ofFrontiers in cellular and infection microbiology · 2026Article
- Comparison of positive detection rates between fluorescent staining and traditional KOH wet mount methods in the diagnosis of superficial fungal skin infections and analysis of factors associated with missed diagnosis.Frontiers in medicine · 2026Article
- Emerging Sexual Transmission of Trichophyton mentagrophytes Genotype VII Infections, United States.Emerging infectious diseases · 2025Article
- Scratching the surface: The rise of antifungal-resistant dermatophytes.Clinical microbiology newsletter · 2025Article
- Cutaneous Infections Caused byJournal of clinical medicine · 2025Review
- Interdigital and Plantar Foot Infections: A Retrospective Analysis of Molecularly Diagnosed Specimens in the United States and a Literature Review.Microorganisms · 2025Article
- Trend analysis and cross nations inequality analysis of infectious skin diseases from 1990 to 2021.Archives of dermatological research · 2025Article
- Molecular Identification of Etiological Agents in Fungal and Bacterial Skin Infections: United States, 2020-2024.Infectious disease reports · 2024Article
- Terbinafine Resistance inJournal of clinical medicine · 2024Article
- Sociodemographic trends and financial burden of emergency department visits due to dermatophytosis in the United States.Archives of dermatological research · 2024Article
- Comprehensive Review of Tinea Capitis in Adults: Epidemiology, Risk Factors, Clinical Presentations, and Management.Journal of fungi (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Dermatophytoses are fungal infections of the skin, hair, and nails that affect approximately 25% of the global population. Occlusive clothing, living in a hot humid environment, poor hygiene, proximity to animals, and crowded living conditions are important risk factors. Dermatophyte infections are named for the anatomic area they infect, and include tinea corporis, cruris, capitis, barbae, faciei, pedis, and manuum. Tinea incognito describes steroid-modified tinea. In some patients, especially those who are immunosuppressed or who have a history of corticosteroid use, dermatophyte infections may spread to involve extensive skin areas, and, in rare cases, may extend to the dermis and hair follicle. Over the past decade, dermatophytoses cases not responding to standard of care therapy have been increasingly reported. These cases are especially prevalent in the Indian subcontinent, and Trichophyton indotineae has been identified as the causative species, generating concern regarding resistance to available antifungal therapies. Antifungal-resistant dermatophyte infections have been recently recognized in the United States. Antifungal resistance is now a global health concern. When feasible, mycological confirmation before starting treatment is considered best practice. To curb antifungal-resistant infections, it is necessary for physicians to maintain a high index of suspicion for resistant dermatophyte infections coupled with antifungal stewardship efforts. Furthermore, by forging partnerships with federal agencies, state and local public health agencies, professional societies, and academic institutions, dermatologists can lead efforts to prevent the spread of antifungal-resistant dermatophytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.